Prognostic factors in childhood anaplastic large cell lymphoma:: results of a large European intergroup study

被引:119
作者
Le Deley, Marie-Cecile [1 ,2 ]
Reiter, Alfred [3 ]
Williams, Denise [4 ]
Delsol, Georges [5 ,6 ]
Oschlies, Ilske [7 ]
McCarthy, Keith [8 ]
Zimmermann, Martin [9 ]
Brugieres, Laurence [10 ]
机构
[1] Inst Gustave Roussy, Biostat & Epidemiol Unit, Villejuif, France
[2] Univ Paris Sud, Le Kremlin Bicetre, France
[3] Univ Giessen, Dept Pediat Hematol & Oncol, D-35390 Giessen, Germany
[4] Addenbrookes Hosp, Dept Pediat, Cambridge, England
[5] Univ Toulouse 3, Ctr Physiopathol Toulouse Purpan, INSERM, U563, Toulouse, France
[6] Ctr Hosp Univ Toulouse, Hop Purpan, Dept Pathol, Toulouse, France
[7] Univ Kiel, Dept Pathol, Hematopathol Sect, Lymph Node Registry, D-24098 Kiel, Germany
[8] Gloucester Hosp, Natl Hlth Serv Fdn Trust, Dept Pathol, Gloucester, England
[9] Med Hochschule Hannover, Dept Pediat Hematol & Oncol, Hannover, Germany
[10] Inst Gustave Roussy, Dept Pediat, Villejuif, France
关键词
D O I
10.1182/blood-2007-07-100958
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To study prognostic factors of progression/relapse, data concerning 225 children enrolled between 1987 and 1997 in Berlin-Frankfurt-Munster, Societe Francaise d'Oncologie Pediatrique and United Kingdom Children's Cancer Study Group prospective studies for the treatment of anaplastic large cell lymphoma (ALCL) were merged. Median follow-up was 9.3 years. Five-year overall survival and event-free survival of the whole population was 81% (95% confidence interval, 76%-86%) and 69% (63%-74%), respectively. B symptoms, mediastinal involvement, skin lesions, visceral involvement, St Jude stage 3-4, Ann Arbor stage 3-4, and elevated lactate dehydrogenase increased the risk of progression/relapse in the univariate analysis. In the multivariate analysis, 3 factors remained significant: mediastinal involvement (relative risk [RR] = 2.1 [1.2-3.5]), visceral involvement defined as lung, liver, or spleen involvement (RR = 2.1 [1.3-3.6]), and skin lesions (FIR = 1.9 [1.1-3.2]). Five-year progression-free survival (PIPS) of the 81 patients with none of these risk factors was 89% [82%-96%], contrasting with a 5-year PFS of 61% [53%-69%] in the 144 patients with at least 1 risk factor (RR = 4.4 [2.2-8.9; P <.001). In conclusion, 3 factors associated with an increased risk of failure in childhood ALCL have been defined: mediastinal involvement, visceral involvement, and skin lesions.
引用
收藏
页码:1560 / 1566
页数:7
相关论文
共 34 条
[1]   ALK-positive lymphoma:: A single disease with a broad spectrum of morphology [J].
Benharroch, D ;
Meguerian-Bedoyan, Z ;
Lamant, L ;
Amin, C ;
Brugières, L ;
Terrier-Lacombe, MJ ;
Haralambieva, E ;
Pulford, K ;
Pileri, S ;
Morris, SW ;
Mason, DY ;
Delsol, G .
BLOOD, 1998, 91 (06) :2076-2084
[2]  
Brugières L, 1998, BLOOD, V92, P3591
[3]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[4]  
Falini B, 1999, BLOOD, V93, P2697
[5]   ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum [J].
Falini, B ;
Bigerna, B ;
Fizzotti, M ;
Pulford, K ;
Pileri, SA ;
Delsol, G ;
Carbone, A ;
Paulli, M ;
Magrini, U ;
Menestrina, F ;
Giardini, R ;
Pilotti, S ;
Mezzelani, A ;
Ugolini, B ;
Billi, M ;
Pucciarini, A ;
Pacini, R ;
Pelicci, PG ;
Flenghi, L .
AMERICAN JOURNAL OF PATHOLOGY, 1998, 153 (03) :875-886
[6]  
HARRIS NL, 1994, BLOOD, V84, P1361
[7]  
JAFFE ES, 2001, TUMORS HAEMATOPOETTI
[8]  
Lamant L, 1996, BLOOD, V87, P284
[9]   Advanced-stage large-cell lymphoma in children and adolescents: Results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: A Pediatric Oncology Group phase III trial [J].
Laver, JH ;
Kraveka, JM ;
Hutchison, RE ;
Chang, M ;
Kepner, J ;
Schwenn, M ;
Tarbell, N ;
Desai, S ;
Weitzman, S ;
Weinstein, HJ ;
Murphy, SB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :541-547
[10]  
LEDELEY MC, 1999, ANN ONCOL, V10, P28